Taken together, our study revealed that the drug transport mediated by ABCB1 or ABCG2 represents a novel mechanism for acquired resistance to citarinostat in human cancer cells; therefore, combination therapies will need to be tested to overcome this clinical problem in the future. This evidence concerns the gene ABCG2 and cancer.